百济神州发布三季度业绩，总收入275.95亿元，同比增长44.21%。其中，泽布替尼收入27.83亿美元，同比增长53%，成为主要收入来源。美国市场贡献最大，单季度收入7.43亿美元，占比74.3%；中国市场销售额为6.61亿元，销量更高但价格差距显著。替雷利珠单抗前三季度收入40.06亿元，同比增长19.23%。代理及其他品种收入33.58亿元，同比增长24.63%。Q3毛利率提升至85.9%，...
Source Link百济神州发布三季度业绩，总收入275.95亿元，同比增长44.21%。其中，泽布替尼收入27.83亿美元，同比增长53%，成为主要收入来源。美国市场贡献最大，单季度收入7.43亿美元，占比74.3%；中国市场销售额为6.61亿元，销量更高但价格差距显著。替雷利珠单抗前三季度收入40.06亿元，同比增长19.23%。代理及其他品种收入33.58亿元，同比增长24.63%。Q3毛利率提升至85.9%，...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.